Latest news and press releases about Prenetics Global Limited (PRE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Price
| Price | $24.19 |
| Market Cap | $411M |
| Exchange | NASDAQ |
| Country | HK |
Valuation Ratios
| Price / Book | 4.43 |
| EV / EBITDA | -5.98 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -49.17% |
| Return on Invested Capital | -42.66% |
| Return on Assets | -44.00% |
| Gross Margin | 62.61% |
| Operating Margin | -35.20% |
| Net Margin | -47.43% |
Related companies: ARMP · ATLN · CDXS · IMDX · MXCT · OSUR · PROF
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of PRE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks